Document is current

Any future updates will be listed below

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Crossref DOI link: https://doi.org/10.1038/srep28124

Published Online: 2016-07-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark